Skip to main content
. 2019 Feb 26;9(3):143–155. doi: 10.1016/j.jpha.2019.02.001

Table 2.

ELISA experimental conditions and main settings for quantitative determination of incretins in biological and formulation matrices, in order to assess blood, plasmatic, serum and tissue concentrations, API pharmacokinetics or biotechnology entrapment efficiency.

Incretin Matrix Sample pretreatment LLOQ (pmol/L) Ref
DPP-IV Krill Dilution – [43]
DPP-IV Rat intestine Homogenization – [44]
Exenatide Human plasma Dried blood spot 23.89 [45]
Exenatide Microspheres – – [46]
Exenatide Microemulsion – – [47]
Exenatide Rat plasma Dilution 19.11a [28,29,48]
Exenatide Rat plasma – 119428.65a [49]
Exenatide Rat plasma – – [50]
Exenatide Rat serum Dilution 23885.73 [51]
Exenatide Rat serum – 19.11a [52]
GLP-1 Mice blood – – [53]
GLP-1 Mice intestinal cells Dilution 4.10a [54]
Lithocholic acid exendin-4 derivatives Rat plasma Dilution 19.11a [12]
a

Manufacturer values; LLOQ, lower limit of quantification.